LINZ PACK
Content
The “Halftime Report” traders give their top picks to watch for the second half. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter. New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions. As elective surgery candidates return to operating rooms, revenue will ramp up. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System.
15 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” ZBH shares.
In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders. According to 19 analysts, the average rating for ZBH stock is “Hold.” The 12-month stock price forecast is $137.64, which is a decrease of -3.32% from the latest price. Some of the biggest medical device companies’ stocks have dropped to attractive prices due to the current COVID-19 pandemic.
You can find your newly purchased ZBH stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business. Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the… Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or https://g-markets.net/calculators/ sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. As of June 15th, there was short interest totaling 3,810,000 shares, an increase of 27.0% from the May 31st total of 3,000,000 shares.
Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers. Zimmer Biomet’s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Centre Asset Management LLC (0.04%), Thomasville National Bank (0.04%), Brookstone Capital Management (0.02%), Jacobs & Co. CA (0.02%), DnB Asset Management AS (0.02%) and DNB Asset Management AS (0.02%).
Provides a general description of the business conducted by this company.
It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. One share of ZBH stock can currently be purchased for approximately $142.37. Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; … The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.
Insiders that own company stock include Arthur J Higgins, Chad F Phipps, Sang Yi and Zuilen Wilfred Van. Zimmer Biomet issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of $7.40-$7.50 for the period, compared to the consensus estimate of $7.06.
Syneos Health’s (SYNH) share price movement is expected to be favorable due to the strength of the company’s Syneos One portfolio and several value-added partnership deals. Get this delivered to your inbox, and more info about our products and services. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
The company issued revenue guidance of $7.29 billion-$7.36 billion, compared to the consensus revenue estimate of $7.14 billion. Zimmer Biomet’s stock performance has been mixed over the past few years. In early 2020, the company’s stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. The technique has proven to be very useful for finding positive surprises.
Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.
Its S.E.T. product category includes sports medicine, biologics, foot and others. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets.
Shareholders of record on Monday, June 26th will be paid a dividend of $0.24 per share on Monday, July 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.67%. The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products. For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. The company’s hip and knee replacement products continue to enjoy solid demand.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. 240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com. Bryan Hanson has an approval rating of 87% among the company’s employees. 66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend. Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat’s FREE daily newsletter.